Chimerix Company Profile (NASDAQ:CMRX)

About Chimerix (NASDAQ:CMRX)

Chimerix logoChimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CMRX
  • CUSIP: N/A
  • Web:
  • Market Cap: $232.33 million
  • Outstanding Shares: 46,651,000
Average Prices:
  • 50 Day Moving Avg: $5.20
  • 200 Day Moving Avg: $5.45
  • 52 Week Range: $3.66 - $6.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.75
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.55 million
  • Price / Sales: 43.04
  • Book Value: $5.65 per share
  • Price / Book: 0.91
  • EBIDTA: ($68,500,000.00)
  • Net Margins: -1,221.34%
  • Return on Equity: -24.07%
  • Return on Assets: -23.24%
  • Current Ratio: 19.11%
  • Quick Ratio: 19.11%
  • Average Volume: 257,957 shs.
  • Beta: 1.54
  • Short Ratio: 8.19
Frequently Asked Questions for Chimerix (NASDAQ:CMRX)

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) issued its earnings results on Tuesday, May, 9th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.01. The business earned $1.08 million during the quarter, compared to analyst estimates of $1.56 million. Chimerix had a negative net margin of 1,221.34% and a negative return on equity of 24.07%. View Chimerix's Earnings History.

Where is Chimerix's stock going? Where will Chimerix's stock price be in 2017?

4 brokerages have issued 12 month price objectives for Chimerix's shares. Their predictions range from $6.00 to $12.00. On average, they anticipate Chimerix's stock price to reach $8.00 in the next year. View Analyst Ratings for Chimerix.

What are analysts saying about Chimerix stock?

Here are some recent quotes from research analysts about Chimerix stock:

  • 1. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (7/17/2017)
  • 2. FBR & Co analysts commented, "We attended Chimerix’s Investor/Analyst Day on April 27 in New York and came away looking forward to further clinical development in 2017 and 2018. Chimerix reported data from the single ascending dose (SAD) study with IV brincidofovir (BCV) and provided additional details on future clinical trials." (5/1/2017)
  • 3. Cowen and Company analysts commented, "CMRX is developing brincidofovir as an inhibitor of several DNA viruses." (4/28/2017)

Who are some of Chimerix's key competitors?

Who are Chimerix's key executives?

Chimerix's management team includes the folowing people:

  • Ernest B. Mario Ph.D., Independent Chairman of the Board
  • Michelle Berrey M.D., President, Chief Executive Officer, Chief Medical Officer, Director
  • Timothy W. Trost CPA, Chief Financial Officer, Senior Vice President, Corporate Secretary
  • Roy W. Ware Ph.D., Chief Manufacturing and Technology Officer
  • Randall Lanier, Chief Science Officer
  • W. Garrett Nichols M.D., Chief Medical Officer
  • Linda M. Richardson, Chief Commercial Officer
  • James M. Daly, Independent Director
  • Martha J. Demski, Independent Director
  • Catherine L. Gilliss Ph.D., Independent Director

Who owns Chimerix stock?

Chimerix's stock is owned by many different of institutional and retail investors. Top institutional investors include Prescott Group Capital Management L.L.C. (0.65%), US Bancorp DE (0.08%) and Moloney Securities Asset Management LLC (0.06%). Company insiders that own Chimerix stock include Ernest Mario, John M Leonard, M Michelle Berrey and Martha J Demski. View Institutional Ownership Trends for Chimerix.

Who sold Chimerix stock? Who is selling Chimerix stock?

Chimerix's stock was sold by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC and US Bancorp DE. Company insiders that have sold Chimerix stock in the last year include Ernest Mario and John M Leonard. View Insider Buying and Selling for Chimerix.

How do I buy Chimerix stock?

Shares of Chimerix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chimerix's stock price today?

One share of Chimerix stock can currently be purchased for approximately $5.12.

MarketBeat Community Rating for Chimerix (NASDAQ CMRX)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Chimerix (NASDAQ:CMRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $8.00 (56.25% upside)

Analysts' Ratings History for Chimerix (NASDAQ:CMRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017FBR & CoReiterated RatingHold$7.00HighView Rating Details
4/28/2017Cowen and CompanyReiterated RatingHold$6.00LowView Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetBuy$12.00N/AView Rating Details
8/9/2016J P Morgan Chase & CoReiterated RatingHold$7.00N/AView Rating Details
3/1/2016Citigroup Inc.Reiterated RatingHoldN/AView Rating Details
2/23/2016William BlairLower Price TargetMarket Perform$12.00 -> $8.00N/AView Rating Details
2/23/2016Barclays PLCDowngradeOverweight -> Equal Weight$12.00 -> $6.00N/AView Rating Details
2/22/2016Morgan StanleyDowngradeEqual Weight -> Underweight$8.00 -> $5.00N/AView Rating Details
1/3/2016Brean CapitalDowngradeHoldN/AView Rating Details
1/3/2016Stifel NicolausDowngradeHoldN/AView Rating Details
12/30/2015EmpireReiterated RatingEqual WeightN/AView Rating Details
12/30/2015Janney Montgomery ScottLower Price TargetNeutral$14.00N/AView Rating Details
9/8/2015Cantor FitzgeraldReiterated RatingBuy$57.00N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for Chimerix (NASDAQ:CMRX)
Earnings by Quarter for Chimerix (NASDAQ:CMRX)
Earnings History by Quarter for Chimerix (NASDAQ CMRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.37)($0.38)$1.56 million$1.08 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.37)($0.32)$0.89 million$1.98 millionViewListenView Earnings Details
11/7/2016Q3($0.39)($0.37)$1.73 million$0.65 millionViewListenView Earnings Details
8/8/2016Q2($0.51)($0.39)$1.98 million$1.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.66)($0.57)$2.79 million$1.20 millionViewN/AView Earnings Details
2/29/2016Q415($0.14)($0.82)$8.07 million$3.10 millionViewListenView Earnings Details
11/5/2015Q315($0.59)($0.70)$5.01 million$2.27 millionViewListenView Earnings Details
8/6/2015Q215($0.58)($0.59)$1.37 million$4.10 millionViewListenView Earnings Details
5/11/2015Q115($0.59)($0.54)$1.19 million$1.20 millionViewListenView Earnings Details
3/6/2015Q414($0.51)($0.52)$1.13 million$1.16 millionViewListenView Earnings Details
11/7/2014Q314($0.41)($0.47)$0.40 million$1.19 millionViewN/AView Earnings Details
8/7/2014Q214($0.46)($0.39)$0.84 million$0.92 millionViewN/AView Earnings Details
5/9/2014Q1 14($0.36)($0.39)$0.85 million$0.78 millionViewN/AView Earnings Details
3/7/2014Q413($0.41)($0.31)$1.19 million$0.88 millionViewN/AView Earnings Details
11/14/2013Q3($0.38)($0.26)ViewListenView Earnings Details
8/14/2013Q2 2013($0.40)($0.91)$1.91 million$0.81 millionViewN/AView Earnings Details
5/13/2013Q1 2013($2.43)($22.58)$1.00 million$1.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Chimerix (NASDAQ:CMRX)
2017 EPS Consensus Estimate: ($1.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.42)($0.34)($0.38)
Q2 20172($0.45)($0.41)($0.43)
Q3 20172($0.54)($0.44)($0.49)
Q4 20172($0.62)($0.49)($0.56)
(Data provided by Zacks Investment Research)


Dividend History for Chimerix (NASDAQ:CMRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Chimerix (NASDAQ:CMRX)
Insider Ownership Percentage: 10.50%
Institutional Ownership Percentage: 66.72%
Insider Trades by Quarter for Chimerix (NASDAQ:CMRX)
Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)
Insider Trades by Quarter for Chimerix (NASDAQ:CMRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/28/2016Ernest MarioDirectorSell100,000$4.64$464,000.00View SEC Filing  
9/15/2016John M LeonardDirectorSell5,000$5.03$25,150.00View SEC Filing  
8/29/2016M Michelle BerreyInsiderBuy22,417$4.47$100,203.99View SEC Filing  
6/24/2016Ernest MarioDirectorBuy50,000$3.70$185,000.00View SEC Filing  
6/24/2016M Michelle BerreyCEOBuy13,188$3.69$48,663.72View SEC Filing  
5/13/2016Ernest MarioDirectorBuy10,000$4.53$45,300.00View SEC Filing  
5/11/2016Ernest MarioDirectorBuy25,000$4.85$121,250.00View SEC Filing  
5/10/2016Ernest MarioDirectorBuy800$4.76$3,808.00View SEC Filing  
3/16/2016Ernest MarioDirectorBuy25,000$5.06$126,500.00View SEC Filing  
3/15/2016Ernest MarioDirectorBuy20,000$5.13$102,600.00View SEC Filing  
3/1/2016Martha J DemskiDirectorBuy10,000$4.89$48,900.00View SEC Filing  
12/29/2015Ernest MarioDirectorBuy125,000$7.09$886,250.00View SEC Filing  
11/2/2015Martha J. DemskiDirectorSell1,126$41.35$46,560.10View SEC Filing  
10/1/2015Martha J. DemskiDirectorSell2,000$37.68$75,360.00View SEC Filing  
9/1/2015Martha J. DemskiDirectorSell2,000$48.18$96,360.00View SEC Filing  
8/21/2015John M LeonardDirectorBuy1,000$47.38$47,380.00View SEC Filing  
7/17/2015Timothy W TrostCFOSell28,000$50.00$1,400,000.00View SEC Filing  
7/1/2015Martha J DemskiDirectorSell2,000$46.03$92,060.00View SEC Filing  
6/1/2015Martha J DemskiDirectorSell2,000$41.58$83,160.00View SEC Filing  
5/1/2015Martha J DemskiDirectorSell2,000$34.71$69,420.00View SEC Filing  
3/2/2015Martha J DemskiDirectorSell2,000$40.18$80,360.00View SEC Filing  
2/2/2015Martha J DemskiDirectorSell2,000$38.38$76,760.00View SEC Filing  
1/2/2015Martha J DemskiDirectorSell2,000$41.08$82,160.00View SEC Filing  
11/5/2014John M LeonardDirectorBuy4,000$29.00$116,000.00View SEC Filing  
9/25/2014Timothy W TrostCFOSell5,000$27.75$138,750.00View SEC Filing  
9/11/2014James NiedelDirectorSell1,099,949$29.39$32,327,501.11View SEC Filing  
9/9/2014Sanderling Venture Partners V,Major ShareholderSell122,950$29.28$3,599,976.00View SEC Filing  
9/8/2014Timothy WollaegerDirectorSell100,000$24.54$2,454,000.00View SEC Filing  
9/5/2014Ernest MarioDirectorBuy10,000$23.19$231,900.00View SEC Filing  
8/25/2014Timothy W TrostCFOSell5,000$25.13$125,650.00View SEC Filing  
7/25/2014Timothy W TrostInsiderSell5,000$22.35$111,750.00View SEC Filing  
6/25/2014Timothy W TrostCFOSell5,000$22.74$113,700.00View SEC Filing  
5/27/2014Ernest MarioDirectorBuy10,000$14.22$142,200.00View SEC Filing  
5/27/2014M Michelle BerreyInsiderBuy14,065$14.22$200,004.30View SEC Filing  
5/27/2014Timothy W TrostCFOSell5,000$17.41$87,050.00View SEC Filing  
4/25/2014Timothy W TrostInsiderSell5,000$18.67$93,350.00View SEC Filing  
3/25/2014Timothy W TrostCFOSell5,000$25.37$126,850.00View SEC Filing  
2/25/2014Timothy W TrostCFOSell5,000$19.29$96,450.00View SEC Filing  
1/27/2014Timothy W TrostCFOSell5,000$18.26$91,300.00View SEC Filing  
12/26/2013Timothy W TrostCFOSell5,000$15.21$76,050.00View SEC Filing  
12/13/2013Ernest MarioDirectorBuy5,000$13.90$69,500.00View SEC Filing  
12/9/2013Rodman L DrakeDirectorBuy1,000$14.35$14,350.00View SEC Filing  
11/25/2013Ernest MarioDirectorBuy8,000$15.20$121,600.00View SEC Filing  
11/19/2013Ernest MarioDirectorBuy7,500$15.25$114,375.00View SEC Filing  
11/15/2013Rodman L DrakeDirectorBuy1,000$15.56$15,560.00View SEC Filing  
10/25/2013Timothy W TrostCFOSell5,000$16.04$80,200.00View SEC Filing  
10/23/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell585,602$15.51$9,082,687.02View SEC Filing  
10/23/2013Vii L P CanaanDirectorSell674,771$15.51$10,465,698.21View SEC Filing  
8/30/2013Ernest MarioDirectorBuy5,064$15.82$80,112.48View SEC Filing  
8/26/2013Ernest MarioDirectorBuy5,960$17.20$102,512.00View SEC Filing  
8/23/2013M Michelle BerreyInsiderBuy5,540$18.70$103,598.00View SEC Filing  
8/20/2013Ernest MarioDirectorBuy4,040$17.48$70,619.20View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Chimerix (NASDAQ:CMRX)
Latest Headlines for Chimerix (NASDAQ:CMRX)
DateHeadline logoZacks Investment Research Upgrades Chimerix, Inc. (CMRX) to "Hold" - July 17 at 5:20 PM logoZacks: Brokerages Expect Chimerix, Inc. (CMRX) Will Announce Quarterly Sales of $1.23 Million - July 15 at 7:50 AM logoChimerix, Inc. (CMRX) Expected to Announce Earnings of -$0.41 Per Share - July 13 at 8:28 PM logoChimerix, Inc. (CMRX) Downgraded to "Sell" at Zacks Investment Research - July 11 at 6:41 PM logoETFs with exposure to Chimerix, Inc. : June 27, 2017 - June 27 at 4:38 PM logo Brokerages Anticipate Chimerix, Inc. (CMRX) Will Announce Quarterly Sales of $1.23 Million - June 21 at 9:08 AM logoChimerix Inc (CMRX) Expected to Post Earnings of -$0.41 Per Share - June 19 at 8:44 PM logoEdited Transcript of CMRX earnings conference call or presentation 9-May-17 12:30pm GMT - June 5 at 9:23 PM logoETFs with exposure to Chimerix, Inc. : June 5, 2017 - June 5 at 4:22 PM logoChimerix Inc (CMRX) Sees Large Decrease in Short Interest - June 3 at 5:28 PM logoChimerix, Inc. :CMRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 - June 2 at 5:50 PM logo$1.23 Million in Sales Expected for Chimerix Inc (CMRX) This Quarter - May 26 at 3:44 PM logoChimerix: This Misunderstood Biotech, Trading Near Cash, Offers Substantial Upside - Seeking Alpha - May 18 at 4:17 PM logoChimerix Inc (CMRX) to Post Q2 2017 Earnings of ($0.45) Per Share, William Blair Forecasts - May 12 at 10:40 AM logoQ2 2017 Earnings Estimate for Chimerix Inc Issued By FBR & Co (CMRX) - May 11 at 9:09 AM logoChimerix Inc (CMRX) Issues Quarterly Earnings Results - May 10 at 4:56 PM logoChimerix outlines plans for DNA virus drug - May 10 at 8:17 AM logoInvestor Network: Chimerix, Inc. to Host Earnings Call - May 9 at 4:23 PM logoChimerix Announces First Quarter 2017 Financial Results - May 9 at 8:12 AM logoPositive Media Coverage Very Likely to Impact Chimerix (CMRX) Share Price - May 3 at 8:54 PM logo Brokerages Anticipate Chimerix Inc (CMRX) Will Post Quarterly Sales of $1.56 Million - May 3 at 2:35 PM logoChimerix to Announce First Quarter 2017 Financial Results on May 9, 2017 - May 2 at 5:29 PM logoChimerix Inc (CMRX) Receives Hold Rating from FBR & Co - May 1 at 7:36 PM logoZacks: Brokerages Expect Chimerix Inc (CMRX) to Announce -$0.37 Earnings Per Share - May 1 at 5:46 PM logoSomewhat Negative Media Coverage Likely to Impact Chimerix (CMRX) Stock Price - April 30 at 11:39 AM logoChimerix Inc (CMRX) Stock Rating Reaffirmed by Cowen and Company - April 29 at 1:02 AM logoChimerix (CMRX) Receives Media Sentiment Rating of 0.56 - April 26 at 11:34 AM logoETFs with exposure to Chimerix, Inc. : April 24, 2017 - April 24 at 4:18 PM logoFavorable News Coverage Somewhat Likely to Affect Chimerix (CMRX) Share Price - April 21 at 5:09 PM logoChimerix to Host Annual Investor Update on April 27, 2017 - April 20 at 4:31 PM logoMedical Device Stocks to Beat Estimates this Earnings Season - April 18 at 4:13 PM logoChimerix (CMRX) Earns Media Impact Rating of -0.08 - April 16 at 11:51 AM logoZacks: Brokerages Expect Chimerix Inc (CMRX) Will Announce Earnings of -$0.37 Per Share - April 10 at 11:27 AM logoETFs with exposure to Chimerix, Inc. : April 7, 2017 - April 7 at 4:22 PM logoCHIMERIX INC Financials - March 8 at 5:07 PM logoEdited Transcript of CMRX earnings conference call or presentation 2-Mar-17 1:30pm GMT - March 2 at 9:38 PM logoChimerix reports 4Q loss - March 2 at 4:38 PM logoCHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 2 at 4:38 PM logoChimerix Announces Fourth Quarter and Full Year 2016 Financial Results - March 2 at 7:23 AM logoQ4 2016 Chimerix Inc Earnings Release - Before Market Open - March 2 at 7:23 AM logoChimerix to Present at Cowen and Company 37th Annual Health Care Conference - February 28 at 1:03 PM logoChimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 - February 23 at 4:21 PM logoChimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings - February 22 at 11:17 AM logo8:06 am Chimerix announces the presentation of final data from the AdVise trial of brincidofovir for the treatment of adenovirus infection in allogeneic hematopoietic cell transplant recipients at the BMT Tandem Meetings; results show highe - February 22 at 11:17 AM logoWill Chimerix (CMRX) Continue to Surge Higher? - January 24 at 4:58 PM logoCHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - January 6 at 4:49 PM logoChimerix (CMRX) Names Randall Lanier as CSO; Roy Ware CMTO - January 5 at 9:56 PM logo4:30 pm Chimerix appoints Randall Lanier, PhD, as Chief Science Officer - January 5 at 9:55 PM logoChimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer - January 5 at 4:54 PM logoChimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference - January 4 at 5:24 PM



Chimerix (CMRX) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff